Table 3.

Effects of saracatinib on Quality of Life measured with the QLQ-C30 and QLQ-BM22 questionnaires.

	Placebo(n = 6)	Saracatinib(n = 6)	Difference(95% C.I.)
QLQ-C30, Global health-related Quality-of-Life score, day 29	69.1 ± 9.9	66.6 ± 10.0	2.5 (-16.79 to 21.84)
QLQ-C30, Pain score, day 29	61.1 ± 9.6	58.3 ± 17.5	2.8 (-18.8 to 23.3)
QLQ-BM22, painful characteristics score, day 29	38.9 ± 14.3	44.4 ± 0	-5.6 (-28.4 to 17.3)
QLQ-BM22 painful sites score, day 29	28.3 ± 12.6	36.0 ± 18.6	-3.9 (-26.4 to 18.6)

Note that higher Global Quality-of-Life scores indicate better Quality-of-Life, while higher pain-related scores reflect worse symptoms.